ProQR Therapeutics (PRQR) Competitors $2.25 -0.01 (-0.44%) Closing price 04:00 PM EasternExtended Trading$2.18 -0.06 (-2.89%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRQR vs. AKBA, AVXL, NRIX, NAGE, PHAR, AVBP, SANA, GYRE, OCS, and DNAShould you be buying ProQR Therapeutics stock or one of its competitors? The main competitors of ProQR Therapeutics include Akebia Therapeutics (AKBA), Anavex Life Sciences (AVXL), Nurix Therapeutics (NRIX), Niagen Bioscience (NAGE), Pharming Group (PHAR), ArriVent BioPharma (AVBP), Sana Biotechnology (SANA), Gyre Therapeutics (GYRE), Oculis (OCS), and Ginkgo Bioworks (DNA). These companies are all part of the "pharmaceutical products" industry. ProQR Therapeutics vs. Its Competitors Akebia Therapeutics Anavex Life Sciences Nurix Therapeutics Niagen Bioscience Pharming Group ArriVent BioPharma Sana Biotechnology Gyre Therapeutics Oculis Ginkgo Bioworks Akebia Therapeutics (NASDAQ:AKBA) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings. Do analysts rate AKBA or PRQR? Akebia Therapeutics currently has a consensus target price of $6.75, indicating a potential upside of 122.77%. ProQR Therapeutics has a consensus target price of $8.00, indicating a potential upside of 255.56%. Given ProQR Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe ProQR Therapeutics is more favorable than Akebia Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akebia Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00ProQR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Which has stronger valuation & earnings, AKBA or PRQR? ProQR Therapeutics has lower revenue, but higher earnings than Akebia Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkebia Therapeutics$160.18M5.02-$69.41M-$0.17-17.82ProQR Therapeutics$20.46M11.57-$30.04M-$0.46-4.89 Which has more volatility and risk, AKBA or PRQR? Akebia Therapeutics has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500. Does the media refer more to AKBA or PRQR? In the previous week, Akebia Therapeutics had 3 more articles in the media than ProQR Therapeutics. MarketBeat recorded 6 mentions for Akebia Therapeutics and 3 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 1.04 beat Akebia Therapeutics' score of 0.80 indicating that ProQR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProQR Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of AKBA or PRQR? 33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 3.0% of Akebia Therapeutics shares are owned by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is AKBA or PRQR more profitable? Akebia Therapeutics has a net margin of -17.91% compared to ProQR Therapeutics' net margin of -238.52%. Akebia Therapeutics' return on equity of 0.00% beat ProQR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Akebia Therapeutics-17.91% N/A -13.47% ProQR Therapeutics -238.52%-61.25%-28.13% SummaryAkebia Therapeutics beats ProQR Therapeutics on 8 of the 15 factors compared between the two stocks. Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRQR vs. The Competition Export to ExcelMetricProQR TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$237.78M$3.06B$5.76B$9.72BDividend YieldN/A2.24%4.40%4.10%P/E RatioN/A20.9030.1925.84Price / Sales11.57390.30474.98187.82Price / CashN/A43.2325.7828.79Price / Book2.479.649.425.99Net Income-$30.04M-$54.08M$3.27B$265.29M7 Day Performance6.13%2.62%2.05%2.53%1 Month Performance0.90%4.05%3.58%0.92%1 Year Performance5.14%9.48%30.09%18.70% ProQR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRQRProQR Therapeutics2.7967 of 5 stars$2.25-0.4%$8.00+255.6%+5.6%$237.78M$20.46M0.00180Positive NewsAKBAAkebia Therapeutics3.9069 of 5 stars$3.11-4.3%$6.75+117.0%+108.5%$861.72M$203.73M-18.29430Analyst RevisionAVXLAnavex Life Sciences3.7408 of 5 stars$9.59-3.5%$44.00+358.8%+50.8%$854.22MN/A-16.8240Analyst ForecastNRIXNurix Therapeutics2.5789 of 5 stars$10.20-3.6%$28.87+183.0%-57.8%$808.83M$54.55M-3.91300News CoveragePositive NewsHigh Trading VolumeNAGENiagen Bioscience1.1617 of 5 stars$10.12+1.0%$13.42+32.6%N/A$799.13M$116.30M48.19120Analyst DowngradePHARPharming Group2.3424 of 5 stars$12.39+6.4%$30.00+142.1%+81.2%$798.20M$297.20M-95.31280Positive NewsGap UpAVBPArriVent BioPharma2.3093 of 5 stars$19.24-1.5%$39.14+103.4%-17.1%$792.31MN/A-4.7940Positive NewsSANASana Biotechnology2.9427 of 5 stars$3.40+2.1%$8.00+135.3%-38.7%$791.90MN/A-3.21380GYREGyre Therapeutics0.0293 of 5 stars$7.85-3.6%N/A-36.3%$783.99M$102.19M785.7940OCSOculis2.974 of 5 stars$18.06+0.9%$35.33+95.6%+49.6%$781.56M$780K-6.842News CoveragePositive NewsEarnings ReportUpcoming EarningsAnalyst ForecastDNAGinkgo Bioworks1.4674 of 5 stars$13.79+4.6%$8.50-38.4%+53.5%$780.25M$227.04M-2.35640Analyst Forecast Related Companies and Tools Related Companies Akebia Therapeutics Competitors Anavex Life Sciences Competitors Nurix Therapeutics Competitors Niagen Bioscience Competitors Pharming Group Competitors ArriVent BioPharma Competitors Sana Biotechnology Competitors Gyre Therapeutics Competitors Oculis Competitors Ginkgo Bioworks Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRQR) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access